Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)

Baulac M.; Rosenow F.; Toledo M.

首页> 外文期刊>Lancet Neurology >Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)

【24h】

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)

机译：Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相关主题

著录项

来源
《Lancet Neurology》 |2017年第2期|102-102|共1页
作者
Baulac M.; Rosenow F.; Toledo M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类神经病学与精神病学;
关键词

客服邮箱：kefu@zhangqiaokeyan.com

客服微信
服务号

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial (vol 16, pg 43, 2017)

著录项

相关主题

期刊订阅